香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 本公告僅作參考，並非收購、購買或認購本公司證券的邀請或要約。 本公告或其任何副本概不得直接或間接在美國，或在刊發或派發本公告屬違法的 任何其他司法權區內刊發或派發。 本公告並非在美國購買或認購任何證券之要約或招攬，亦不構成其一部分。本公 告所述證券並未且將不會根據《1933年美國證券法》（「美國證券法」）登記，亦不會 在美國提呈或出售，除非根據美國證券法作出登記或獲豁免或為毋須根據美國證 券 法 作 出 登 記 之 交 易 。 本 公 司 無 意 根 據 美 國 證 券 法 登 記 本 公 告 內 所 指 之 任 何 證 券，或在美國進行證券之公開發售。 Laekna, Inc. 來凱醫藥有限公司 （於開曼群島註冊成立之有限公司） （股份代號：2105） 完成根據一般授權配售新股 獨家整體協調人及獨家配售代理 董 事 會 欣 然 宣 佈 ...

Core Viewpoint - 来凯医药-B plans to place 36 million shares, representing approximately 8.1% of the enlarged share capital post-placement, at a price of HKD 16.30 per share, which is about a 9.5% discount to the closing price of HKD 18.01 on September 9 [1] Fundraising Details - The total expected fundraising amount is HKD 586.8 million, with net proceeds estimated at HKD 577.5 million [1] - Approximately 90% of the raised funds will be allocated to the research and development of clinical and pre-clinical pipeline projects, while the remaining 10% will be used for general and corporate purposes [1]

Core Viewpoint - The company, 来凯医药-B (02105.HK), has announced a placement agreement to issue 36 million shares at a price of HKD 16.30 per share, which represents approximately 8.8% of the current issued share capital and about 8.1% of the enlarged issued share capital after the placement [1] Summary by Relevant Sections - **Placement Details** - The company will issue a total of 36 million shares through an exclusive placement agent [1] - The placement price is set at HKD 16.30 per share [1] - **Financial Implications** - The estimated gross proceeds from the placement will be approximately HKD 586.8 million, with net proceeds expected to be around HKD 577.5 million [1] - **Use of Proceeds** - Approximately 90% of the net proceeds will be allocated for research and development of clinical and pre-clinical pipeline projects [1] - The remaining 10% will be used for general and corporate purposes [1]

Core Viewpoint - The company plans to issue a total of 36 million placement shares, representing approximately 8.1% of the enlarged issued share capital post-completion, at a price of HKD 16.30 per share, which is a discount of about 9.5% compared to the closing price of HKD 18.01 on September 9 [1] Summary by Relevant Categories Fundraising Details - The total amount raised from the placement, assuming all shares are fully subscribed, will be HKD 586.8 million, with the estimated net proceeds from the placement being HKD 577.5 million [1] Use of Proceeds - Approximately 90% of the net proceeds will be allocated to research and development of clinical and pre-clinical pipeline projects, while about 10% will be used for general and corporate purposes [1]

Group 1 - The company, 来凯医药-B (02105), announced a proposed placement of 36 million shares, representing approximately 8.1% of the enlarged issued share capital post-completion [1] - The placement price is set at HKD 16.30 per share, which reflects a discount of about 9.5% compared to the closing price of HKD 18.01 on September 9 [1] - If all 36 million shares are fully subscribed, the total proceeds from the placement will amount to HKD 586.8 million, with the estimated net proceeds being HKD 577.5 million [1] Group 2 - Approximately 90% of the net proceeds from the placement will be allocated to research and development of clinical and preclinical pipeline projects [1] - The remaining 10% of the net proceeds will be used for general and corporate purposes [1]

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 本公告僅作參考，並非收購、購買或認購本公司證券的邀請或要約。 本公告或其任何副本概不得直接或間接在美國，或在刊發或派發本公告屬違法的 任何其他司法權區內刊發或派發。 本公告並非在美國購買或認購任何證券之要約或招攬，亦不構成其一部分。本公 告所述證券並未且將不會根據《1933年美國證券法》（「美國證券法」）登記，亦不會 在美國提呈或出售，除非根據美國證券法作出登記或獲豁免或為毋須根據美國證 券 法 作 出 登 記 之 交 易 。 本 公 司 無 意 根 據 美 國 證 券 法 登 記 本 公 告 內 所 指 之 任 何 證 券，或在美國進行證券之公開發售。 Laekna, Inc. 來凱醫藥有限公司 （於開曼群島註冊成立之有限公司） （股份代號：2105） 根據一般授權配售新股 獨家整體協調人及獨家配售代理 董 事 會 欣 然 宣 佈 ， ...

Core Viewpoint - The company, 来凯医药-B (02105), announced the issuance of a total of 2.73 million ordinary shares on September 5, 2025, to fulfill the vesting of RSUs granted under the 2024 Share Incentive Plan [1] Summary by Relevant Categories - **Share Issuance** - The company will issue 2.73 million ordinary shares [1] - **Incentive Plan** - The share issuance is related to the vesting of RSUs under the 2024 Share Incentive Plan [1]

Core Viewpoint - 来凯医药-B (02105) announced the issuance of a total of 2.73 million ordinary shares on September 5, 2025, to fulfill the vesting of RSUs granted under the 2024 share incentive plan [1] Summary by Relevant Categories - **Company Actions** - The company will issue 2.73 million ordinary shares [1] - This issuance is part of the 2024 share incentive plan [1] - **Future Plans** - The shares will be issued on September 5, 2025 [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 來凱醫藥有限公司 呈交日期： 2025年9月7日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 普通股 | | | 股份類別 | 不適用 | | 於香港聯交所上市 | | 是 | | | 證券代號 (如上市) | | 02105 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 事件 | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | 每股發行/出售價 ...

Core Viewpoint - The report emphasizes the sustained high growth in the innovative pharmaceutical and medical device sectors, recommending continued investment in these areas [1]. Investment Highlights - The report maintains a recommendation for innovative pharmaceuticals and medical devices, highlighting the potential for value re-evaluation in the Pharma sector, with specific buy ratings for companies such as 恒瑞医药, 翰森制药, 三生制药, and 华东医药 [2]. - It continues to recommend Biopharma/Biotech companies that are gradually realizing their innovative pipelines and entering a performance growth phase, with buy ratings for 科伦博泰生物, 信达生物, 康方生物, 新诺威, 映恩生物, 京新药业, 微芯生物, 特宝生物, 我武生物, and 来凯医药 [2]. - The report also suggests investment in CXO and upstream pharmaceutical companies benefiting from innovation and recovery, maintaining buy ratings for 百普赛斯, 药明康德, 药明合联, 泰格医药, and 美诺华 [2]. - It recommends leading medical device companies expected to recover, with buy ratings for 微创医疗, 联影医疗, and 惠泰医疗 [2]. Market Performance - In the first week of September 2025, the A-share pharmaceutical sector outperformed the broader market, with the SW pharmaceutical and biotech index rising by 1.4% while the Shanghai Composite Index fell by 1.2% [3]. - Within the biopharmaceutical sector, the chemical preparations segment saw a notable increase of 4.5%, while biological products and medical services rose by 1.9% and 1.7%, respectively [3]. - The top-performing stocks included 海辰药业 (+28.7%), 长春高新 (+24.2%), and 百花医药 (+21.3%), while the worst performers were 舒泰神 (-24.0%), 广生堂 (-15.8%), and 塞力医疗 (-15.6%) [3]. - In the Hong Kong market, the healthcare sector also outperformed, with the Hang Seng Healthcare index rising by 7.0% and the biotech index by 7.3%, compared to a 1.4% increase in the Hang Seng Index [3]. - The top gainers in the Hong Kong market were 三叶草生物-B (+99%), 圣诺医药-B (+62%), and 加科思-B (+41%), while the biggest losers included 美中嘉和 (-11%), 科笛-B (-9%), and 思路迪医药股份 (-6%) [3]. - In the US market, the healthcare sector performed in line with the broader market, with the S&P Healthcare Select Sector Index increasing by 0.3%, matching the S&P 500's performance [4]. - The top gainers in the US healthcare sector included 德康医疗 (+7%), 生物基因 (+6%), and 环球健康服务 (+5%), while the largest declines were seen in KENVUE (-10%), REVVITY (-4%), and MOLINA HEALTHCARE (-3%) [4].